Biotech

On Monday, Palantir Technologies Inc. (NASDAQ:PLTR) co-founder Joe Lonsdale urged a tech-driven transformation of the Food and Drug Administration, warning that bureaucratic inertia is putting the U.S. behind China in the biotech race. What Happened: In a blog post, Lonsdale said the FDA's current...

Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) stock experienced a drop of 5.54% on Thursday, followed by a remarkable recovery of 14.29% in after-hours trading. What Happened: Sonnet BioTherapeutics’ stock fell by 5% during regular trading hours on Thursday. The drop was attributed to...

Changpeng Zhao, the founder of cryptocurrency exchange Binance (CRYPTO: BNB), said Tuesday that he made a personal donation of $10 million to support Ethereum (CRYPTO: ETH) co-founder Vitalik Buterin’s biotech initiative. What Happened: Zhao, known popularly as “CZ,” ...

ARK Invest founder Cathie Wood is betting big on a new frontier in biotechnology, one she says could unlock massive market opportunity, and two companies are already leading the way, with the potential to grow 10x from their current levels. What Happened: Speaking on The Diary of a CEO podcast last...

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Monday revealed results from the Phase 3 IMforte study of Zepzelca (lurbinectedin) in combination with Roche Holdings AG’s (OTC:RHHBY) Tecentriq (atezolizumab) as a first-line maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) revealed topline results on Monday from its Phase 2b CORAL trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) (N=165). The primary endpoint in the CORAL trial was achieved, demonstrating statistically...

Verastem Oncology Inc (NASDAQ:VSTM) released on Monday updated data from the dose escalation phase of the Phase 1/2 trial of GFH375 (known as VS-7375 in the U.S.). As of May 16, 2025, 23 efficacy-evaluable patients with pancreatic ductal adenocarcinoma (PDAC) and 12 efficacy-evaluable patients...

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the first quarter of 2025 adjusted earnings per share was $3.02. That’s down from $3.67 a year ago, beating the analyst consensus of $2.52. The company reported sales of $2.43 billion, up 6% year over year on a reported basis, 8% on constant...

Revvity Inc. (NYSE:RVTY) stock is trading higher on Monday after the company reported better-than-expected first-quarter 2025 earnings. The Waltham, Massachusetts-based company reported first-quarter sales of $664.76 million, down from $709.07 million, beating the consensus of $661.18 million...

Novavax, Inc. (NASDAQ:NVAX) on Tuesday released preliminary results from the SHIELD-Utah study investigating the effects of systemic and local reactogenicity of COVID-19 vaccine doses in Utah. SHIELD-Utah was a prospective, interventional study conducted at the University...

Abbott Laboratories (NYSE:ABT) will release its first-quarter earnings results before the opening bell on Wednesday, April 16. Analysts expect the company to report quarterly earnings at $1.07 per share, up from 98 cents per share in the year-ago period. According to data from Benzinga Pro, Abbott...

Shares of PMGC Holdings Inc. (NASDAQ:ELAB) were trading higher in premarket session Thursday, but dipped over 11% at last check. The company’s subsidiary, Northstrive Biosciences Inc., formed a development and license agreement with biotechnology innovator Yuva Biosciences Inc. to advance...

Pacific Biosciences of California Inc. (NASDAQ:PACB) on Wednesday announced preliminary revenue of $36.9 million versus a consensus of $33.49 million. The company said the first quarter met expectations, despite impacts from ongoing uncertainty in NIH funding in the United States and broader...

Biogen Inc. (NASDAQ:BIIB) submitted an unsolicited bid to acquire all of the outstanding shares of Sage Therapeutics Inc. (NASDAQ:SAGE) that it does not already owned by Biogen for $7.22 per share. Goldman Sachs analyst Salveen Richter believes the proposal makes strategic sense, considering the...

Ark Invest CEO Cathie Wood is doubling down on genomics. What Happened: Pacific Biosciences of California Inc. (NASDAQ:PACB), known as PacBio, is biotech’s new kid on the block. The company's Vega sequencer might be the spark that reignites the genomics flame in Ark Invest's portfolios. ARK...